What is Moderna?
Moderna is recognized as a pioneer in mRNA medicine, fundamentally reshaping the landscape of vaccine development and therapeutic delivery. By integrating advanced computational biology with sophisticated manufacturing capabilities, the company has transitioned from a research-focused entity into a commercial-stage powerhouse. Its market position is defined by a robust portfolio of mRNA-based candidates that address significant unmet medical needs. The firm's ability to rapidly iterate on its platform technology has allowed it to maintain a competitive edge in the global life sciences industry, supported by a diverse ecosystem of institutional backers and strategic partners who provide both capital and operational expertise.
How much funding has Moderna raised?
Moderna has raised a total of $8.1B across 19 funding rounds:
Other Financing Round
$25M
Other Financing Round
$450M
Multiple Rounds
$502M
Multiple Rounds
$1.2B
Multiple Rounds
$2.8B
Other Financing Round
$750M
Multiple Rounds
$2.1B
Other Financing Round (2014): $25M featuring Alexion Pharmaceuticals
Other Financing Round (2015): $450M backed by Invus, Wellington Management, Viking Global Investors, Alexion Pharmaceuticals, RA Capital Management, and AstraZeneca
Grant (2016): $20M with participation from Bill & Melinda Gates Foundation
Grant (2016): $8M led by BARDA
Other Financing Round (2016): $474M supported by Invus, Wellington Management, Viking Global Investors, RA Capital Management, Alexion Pharmaceuticals, and AstraZeneca
Other Financing Round (2018): $500M featuring Alexandria Venture Investments, ADIA, ArrowMark Partners, EDBI, Viking Global Investors, BB Biotech Ventures, Pictet Private Equity Investors S.A., Julius Baer Group, Fidelity Management & Research Company, and Sequoia Capital China
Corporate Investment (2018): $125M backed by Merck
Stock Issuance/Offering (2018): $604.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $500M, investors not publicly disclosed
Grant (2020): $483M supported by BARDA
Stock Issuance/Offering (2020): $1.3B, investors not publicly disclosed
Grant (2020): $472M, investors not publicly disclosed
Other Financing Round (2024): $750M with participation from Blackstone
Other Financing Round (2025): $590M led by Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $1.5B supported by Ares Management Corporation
Unspecified (2025): $54.3M, investors not publicly disclosed
Key Investors in Moderna
Flagship Pioneering
Flagship Pioneering is a Cambridge-based firm of scientists and professionals dedicated to building companies that transform human health and sustainability through innovative research.
Wellington Management
Wellington Management is a global, independent investment firm providing institutional clients with tailored portfolio management and research-driven solutions across diverse asset classes.
Viking Global Investors
Viking Global Investors is a research-intensive firm that utilizes fundamental analysis to select long-term equity interests across global industries and geographies.
What's next for Moderna?
With the recent influx of $54.3M, Moderna is well-positioned to scale its next-generation therapeutic programs. The company's strategic roadmap focuses on deepening its research into autoimmune challenges and oncology, while simultaneously optimizing its global supply chain for broader vaccine distribution. As the firm moves beyond its initial commercial successes, the focus shifts toward long-term sustainability and the diversification of its clinical assets. Investors and industry analysts are closely monitoring the company's ability to translate its mRNA platform into a broader suite of chronic disease treatments, which remains the primary driver for its long-term valuation and market influence.
See full Moderna company page
